Interpace Biosciences' Revenue Plummets 14.5% Amid PancraGEN Coverage Loss

TL;DR

**IDXG is bleeding cash and revenue after losing Medicare coverage for its flagship test; steer clear until they prove a viable path forward.**

AI Summary

Interpace Biosciences, Inc. (IDXG) reported a significant decline in revenue and net income for the nine months ended September 30, 2025, with net revenue falling to $29.504 million from $34.515 million in the prior year, a 14.5% decrease. Net income also dropped substantially to $1.918 million from $4.821 million, representing a 60.2% decrease. This downturn is primarily attributed to the loss of Medicare coverage for its PancraGEN molecular test, following Local Coverage Determination (LCD) L39365, which took effect on April 24, 2025. In response, the company implemented a Restructuring Plan in January 2025, incurring $0.7 million in severance costs and reducing its workforce to align with the reduced business scope. Despite these challenges, IDXG maintains a positive liquidity outlook, with $1.423 million in cash and cash equivalents as of September 30, 2025, and $2.1 million as of November 7, 2025. The company anticipates current cash and forecasted receipts will cover its needs for the next twelve months, while actively exploring strategic alternatives and financing options to enhance liquidity, though its delisting from Nasdaq in February 2021 complicates capital raising efforts.

Why It Matters

This filing reveals a critical juncture for Interpace Biosciences. The loss of Medicare coverage for PancraGEN, a key molecular test, directly impacts IDXG's revenue and profitability, signaling a significant challenge to its core business model. For investors, this raises concerns about future growth and the company's ability to innovate and secure reimbursement for new tests in a competitive diagnostics market. Employees face job insecurity due to the Restructuring Plan, which included workforce reductions. Customers, particularly those relying on PancraGEN, will need to seek alternative diagnostic solutions, potentially impacting patient care. The broader market will watch to see how IDXG navigates this regulatory and financial headwind, especially given its delisted status, which limits access to capital compared to competitors.

Risk Assessment

Risk Level: high — The company experienced a 60.2% drop in net income, from $4.821 million to $1.918 million, and a 14.5% decrease in net revenue, from $34.515 million to $29.504 million, for the nine months ended September 30, 2025. This significant financial decline, coupled with the loss of Medicare coverage for its PancraGEN test and its delisted status from Nasdaq since February 2021, severely impacts its ability to raise capital and sustain operations, indicating a high risk profile.

Analyst Insight

Investors should exercise extreme caution and consider divesting, as the significant revenue and net income decline, coupled with the loss of a key product's Medicare coverage and delisted status, presents substantial headwinds. Monitor closely for concrete evidence of successful strategic alternatives or new revenue streams before considering any new investment.

Financial Highlights

debt To Equity

N/A

revenue

$29.504M

operating Margin

N/A

total Assets

$9.130M

total Debt

$1.0M

net Income

$1.918M

eps

N/A

gross Margin

N/A

cash Position

$1.423M

revenue Growth

-14.5%

Revenue Breakdown

Key Numbers

• $29.504M — Net Revenue (Decreased from $34.515 million for the nine months ended September 30, 2024, a 14.5% decline.)
• $1.918M — Net Income (Decreased from $4.821 million for the nine months ended September 30, 2024, a 60.2% decline.)
• $1.423M — Cash and Cash Equivalents (As of September 30, 2025, down from $1.461 million at December 31, 2024.)
• $0.7M — Severance and Related Costs (Incurred for the nine months ended September 30, 2025, due to the Restructuring Plan.)
• $1.0M — Term Loan Outstanding (Balance with BroadOak at September 30, 2025.)
• 4,428,539 — Common Shares Outstanding (As of November 7, 2025.)
• $9.130M — Total Current Assets (As of September 30, 2025, down from $11.773 million at December 31, 2024.)
• $5.945M — Total Current Liabilities (As of September 30, 2025, down from $10.615 million at December 31, 2024.)
• $2.507M — Operating Income from Continuing Operations (For the nine months ended September 30, 2025, a decrease from $6.047 million in the prior year.)

Key Players & Entities

• Interpace Biosciences, Inc. (company) — registrant
• BroadOak Fund V, L.P. (company) — lender for $8.0 million term loan
• Novitas (company) — local Medicare Administrative Contractor
• First Coast Service Options, Inc. (company) — Medicare Administrative Contractor
• PancraGEN (product) — molecular test that lost Medicare coverage
• Nasdaq (regulator) — exchange from which IDXG was delisted
• Ampersand Capital Partners (company) — previous secured promissory note holder
• 1315 Capital II, L.P. (company) — previous secured promissory note holder
• CMS (regulator) — Centers for Medicare & Medicaid Services

FAQ

Risk Factors

• Loss of Medicare Coverage [high — regulatory]: The company experienced a significant revenue decline due to the loss of Medicare coverage for its PancraGEN molecular test, effective April 24, 2025. This was a direct result of Local Coverage Determination (LCD) L39365, which has materially impacted the company's primary revenue stream.
• Liquidity Concerns [medium — financial]: While the company reported $1.423 million in cash as of September 30, 2025, and anticipates covering needs for the next twelve months, its delisting from Nasdaq in February 2021 complicates capital raising efforts. The company is actively exploring strategic alternatives and financing options.
• Restructuring and Workforce Reduction [medium — operational]: In response to the revenue downturn, the company implemented a Restructuring Plan in January 2025, incurring $0.7 million in severance costs and reducing its workforce. This indicates a significant scaling back of operations.
• Dependence on Reimbursement Policies [high — regulatory]: The company's financial performance is highly sensitive to changes in healthcare reimbursement policies, particularly Medicare. The loss of coverage for PancraGEN highlights the inherent risk associated with relying on specific LCDs for revenue generation.

Industry Context

The molecular diagnostics market is highly competitive and subject to evolving reimbursement landscapes. Companies like Interpace Biosciences rely heavily on securing favorable coverage decisions from payers, such as Medicare, for their diagnostic tests. Changes in these policies, as seen with LCD L39365, can rapidly alter a company's revenue trajectory.

Regulatory Implications

The company's reliance on Medicare coverage makes it highly susceptible to regulatory changes and policy shifts. The loss of coverage for PancraGEN underscores the critical importance of navigating and complying with Medicare's Local Coverage Determinations.

What Investors Should Do

1. Monitor the company's progress in exploring strategic alternatives and financing options, as liquidity remains a key concern.
2. Closely track any updates regarding potential changes to Medicare coverage policies or the development of new tests that could offset the impact of the PancraGEN coverage loss.
3. Evaluate the company's ability to manage its cost structure effectively following the recent restructuring efforts.

Key Dates

• 2025-04-24: Loss of Medicare Coverage for PancraGEN — Effective date of LCD L39365, leading to a significant decline in revenue for the company.
• 2025-01-01: Restructuring Plan Implementation — Company initiated cost-saving measures, including workforce reduction and severance costs, in response to business challenges.
• 2021-02-01: Delisting from Nasdaq — This event complicates the company's ability to raise capital through equity markets.

Glossary

Local Coverage Determination (LCD)

Decisions made by Medicare contractors on whether a particular item or service is considered reasonable and necessary for Medicare beneficiaries in a specific geographic area. (The loss of Medicare coverage for PancraGEN was directly tied to an LCD, significantly impacting the company's revenue.)

Restructuring Plan

A plan implemented by a company to reorganize its business operations, often involving cost reductions, workforce adjustments, or divestitures, to improve financial performance. (IDXG implemented a restructuring plan in response to declining revenues, incurring severance costs and reducing its workforce.)

Year-Over-Year Comparison

For the nine months ended September 30, 2025, Interpace Biosciences reported a 14.5% decrease in net revenue to $29.504 million compared to $34.515 million in the prior year. Net income saw a substantial decline of 60.2%, falling to $1.918 million from $4.821 million. Total current assets decreased from $11.773 million to $9.130 million, while total current liabilities also decreased from $10.615 million to $5.945 million.

Filing Documents

• form10-q.htm (10-Q) — 949KB
• ex31-1.htm (EX-31.1) — 19KB
• ex31-2.htm (EX-31.2) — 19KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• 0001493152-25-021928.txt ( ) — 4908KB
• idxg-20250930.xsd (EX-101.SCH) — 35KB
• idxg-20250930_cal.xml (EX-101.CAL) — 61KB
• idxg-20250930_def.xml (EX-101.DEF) — 110KB
• idxg-20250930_lab.xml (EX-101.LAB) — 287KB
• idxg-20250930_pre.xml (EX-101.PRE) — 230KB
• form10-q_htm.xml (XML) — 741KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1. Unaudited Interim Condensed Consolidated Financial Statements Condensed Consolidated Balance Sheets at September 30, 2025 (unaudited) and December 31, 2024 3 Condensed Consolidated Statements of Operations for the three and nine-month periods ended September 30, 2025 and 2024 (unaudited) 4 Condensed Consolidated Statements of Stockholders' Deficit for the three and nine-month periods ended September 30, 2025 and 2024 (unaudited) 5 Condensed Consolidated Statements of Cash Flows for the nine-month periods ended September 30, 2025 and 2024 (unaudited) 6 Notes to Unaudited Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 30 Item 4.

Controls and Procedures

Controls and Procedures 31

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 31 Item 1A.

Risk Factors

Risk Factors 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 31 Item 3. Defaults Upon Senior Securities 31 Item 4. Mine Safety Disclosures 31 Item 5. Other Information 31 Item 6. Exhibits 32

Signatures

Signatures 33 2 PART I. FINANCIAL INFORMATION INTERPACE BIOSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) September 30, December 31, 2025 2024 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 1,423 $ 1,461 Accounts receivable 5,966 8,544 Other current assets 1,741 1,768 Total current assets 9,130 11,773 Property and equipment, net 1,541 1,361 Operating lease right of use assets 1,320 1,613 Other long-term assets 45 45 Total assets $ 12,036 $ 14,792 LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Accounts payable $ 1,411 $ 1,659 Accrued salary and bonus 1,447 2,207 Other accrued expenses 1,450 1,799 Note payable at fair value 977 4,290 Current liabilities of discontinued operations 660 660 Total current liabilities 5,945 10,615 Operating lease liabilities, net of current portion 864 1,183 Other long-term liabilities 5,525 5,211 Total liabilities 12,334 17,009 Commitments and contingencies (Note 8) - Stockholders' deficit: Redeemable preferred stock, $ .01 par value; 5,000,000 shares authorized, 47,000 shares Series C issued and outstanding - - Common stock, $ .01 par value; 100,000,000 shares authorized; 4,569,333 and 4,539,663 shares issued, respectively; 4,428,539 and 4,409,323 shares outstanding, respectively 407 406 Additional paid-in capital 234,829 234,811 Accumulated deficit ( 233,462 ) ( 235,380 ) Treasury stock, at cost ( 140,794 and 130,340 shares, respectively) ( 2,072 ) ( 2,054 ) Total stockholders' deficit ( 298 ) ( 2,217 ) Total liabilities and stockholders' deficit $ 12,036 $ 14,792 The accompanying notes are an integral part of these condensed consolidated financial statements 3 INTERPACE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited, in thousands, except for per share data) 2025 2024 2025 2024 For Th

View Full Filing

View this 10-Q filing on SEC EDGAR